Recently published acute myocardial infarction market insights report includes a comprehensive understanding of current treatment practices, acute myocardial infarction emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Acute myocardial infarction market summary
The total acute myocardial infarction treatment market size was found to be USD 1.6 billion in 2025 in the leading markets.
The United States accounted for the largest acute myocardial infarction treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
In 2025, the 7MM had approximately 1.5 million incident cases of AMI. The incidence is projected to increase during the forecast period (2025−2034).
Leading acute myocardial infarction companies, such as Idorsia Pharmaceuticals, Recardio, Kancera, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Faraday Pharmaceuticals, Novo Nordisk, CeleCor Therapeutics, and others, are developing new acute myocardial infarction treatment drugs that can be available in the acute myocardial infarction market in the coming years.
The promising acute myocardial infarction therapies in clinical trials include Selatogrel, Dutogliptin, KAND567, Milvexian, ProtheraCytes, FDY-5301, Ziltivekimab, Zalunfiban, and others.
Among available therapies, agents such as evolocumab are expected to generate significant revenue, particularly in the secondary prevention setting.
Discover AMI market CAGR and revenue growth at www.delveinsight.com.
Key factors driving the growth of the acute myocardial infarction market
Rising AMI incidence: As per DelveInsight’s analysis, in 2025, the US accounted for approximately 829K incident cases of AMI. These cases are expected to increase during the forecast period (2026−2036) owing to rising rates of lifestyle-related risk factors such as obesity, diabetes, and hypertension, alongside increasing population, improved diagnostic methods, and advancements in medical technology, allowing for better treatment.
Advancements in AMI diagnosis and treatment: in recent decades, the diagnosis and treatment of acute myocardial infarction have been advanced with improvements in revascularization strategies (PCI or CABG), device technology and medications. Widespread use of intravascular imaging modalities can improve the prognosis of patients after PCI, which can further help identify AMI, boosting the market size of the therapeutic market.
Approval of AGEPHA Pharma’s LODOCO: With the approval of AGEPHA Pharma’s LODOCO, patients with residual inflammatory risk now have, for the first time, an FDA-approved treatment option specifically designed to reduce the risk of cardiovascular disease.
Selatogrel–A breakthrough in AMI treatment: Idorsia Pharmaceuticals and Viatris are developing selatogrel, a self-administering drug with an auto-injector. If authorized, it has the potential to prevent irreparable and frequently deadly cardiovascular damage caused by blood clots in the critical few hours following an AMI before medical help arrives.
Emergence of Novel AMI Drug Classes: Various companies, such as Idorsia Pharmaceuticals and Faraday Pharmaceuticals, are developing drugs with novel mechanisms of action for treating AMI, such as FXIa inhibitors, DPP4 inhibitors, siRNAs, and others. Thus, these drugs with novel mechanisms of action would further assist in addressing the untapped patient pool.
Rising AMI clinical trial activity: the AMI pipeline includes several drugs in mid and late-stage development, poised for approval in the near future. The expected launch of therapies such as Selatogrel (Idorsia Pharmaceuticals and Viatris), FDY-5301 (Faraday Pharmaceuticals), Dutogliptin (Recardio), Ziltivekimab (Novo Nordisk), Milvexian (Bristol Myers Squibb and Johnson & Johnson Innovative Medicine), Zalunfiban (CeleCor Therapeutics), and others shall further create a positive impact on the AMI market.
Acute myocardial infarction market analysis
The current acute myocardial infarction treatment landscape is divided into several therapeutic categories, including antiplatelet drugs, anticoagulants, vasodilators, beta blockers, lipid-lowering therapies, ACE inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers.
Commonly used medications for AMI management include tenecteplase (TNKASE) from Genentech, evolocumab (REPATHA) from Amgen, and alirocumab (PRALUENT) from Regeneron/Sanofi, among others.
With the recent FDA approval of AGEPHA Pharma’s LODOCO, patients with persistent inflammatory risk now have, for the first time, a treatment specifically authorised to lower cardiovascular disease risk.
Numerous pharmaceutical companies continue to advance AMI therapies. Major developers, such as Idorsia Pharmaceuticals and Viatris (Selatogrel), Recardio (Dutogliptin), Faraday Pharmaceuticals (FDY-5301), Novo Nordisk (Ziltivekimab), Bristol Myers Squibb and Johnson & Johnson Innovative Medicine (Milvexian), CeleCor Therapeutics (Zalunfiban), Kancera (KAND567) and CellProthera with BioCardia (ProtheraCytes), are progressing their pipeline candidates across various clinical stages.
However, recent trial setbacks involving the SGLT2 inhibitors Jardiance and Farxiga/Forxiga, which failed to meet the primary composite outcome of reducing cardiovascular death and heart-failure–related hospitalisations in MI patients, have cast doubt on expanding the use of this drug class for AMI treatment.
Acute myocardial infarction competitive landscape
Some of the AMI drugs under development include Selatogrel (Idorsia Pharmaceuticals and Viatris), FDY-5301 (Faraday Pharmaceuticals), Dutogliptin (Recardio), Ziltivekimab (Novo Nordisk), Milvexian (Bristol Myers Squibb and Johnson & Johnson Innovative Medicine), Zalunfiban (CeleCor Therapeutics), and others.
Idorsia Pharmaceuticals and Viatris’ Selatogrel is a powerful, highly selective, fast-onset, and reversible P2Y12 inhibitor in development for treating acute myocardial infarction (AMI) in individuals at elevated risk of a recurrent event. It is designed for patient self-administration via a subcutaneous autoinjector at the first signs of AMI, producing effects within about 15 minutes that last 4–8 hours. Selatogrel has also been granted Fast Track Designation by the FDA. The company is running a Phase III trial targeting roughly 14,000 participants at risk of recurrent AMI, with completion of enrollment anticipated in 2026.
Faraday Pharmaceuticals’ FDY-5301 is a proprietary elemental reducing agent formulated with sodium iodide. Results from a Phase II study in STEMI patients indicated it was well tolerated and showed promising signs of reducing cardiac injury. A Phase III trial (AMI-3) is now underway to evaluate FDY-5301’s ability to decrease cardiovascular mortality and heart failure in patients with anterior STEMI undergoing PCI. This study is being conducted under a special protocol agreement with the US FDA.
CeleCor Therapeutics’ Zalunfiban is an investigational, next-generation GPIIb/IIIa inhibitor engineered for use by frontline medical teams, including first responders and emergency department personnel. It can be delivered via a subcutaneous injection that fits a full dose into less than 1 millilitre (under ¼ teaspoon). The drug reaches its peak activity in about 15 minutes, and its antiplatelet action fades within roughly two hours, returning to baseline by four hours.
The anticipated launch of these emerging therapies are poised to transform the acute myocardial infarction market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the acute myocardial infarction market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Recent developments in the acute myocardial infarction market
As per the company’s 2025 Q2 presentation, Selatogrel is undergoing evaluation in the Phase III SOS-AMI study, with enrolment already started in Japan and expected to be fully completed by 2026.
In March 2025, Sungen Biomedical announced that SGC001, the world’s first monoclonal antibody drug for AMI, had been granted Fast Track designation by the US FDA.
